CN114480463A - 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用 - Google Patents

一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用 Download PDF

Info

Publication number
CN114480463A
CN114480463A CN202011168321.4A CN202011168321A CN114480463A CN 114480463 A CN114480463 A CN 114480463A CN 202011168321 A CN202011168321 A CN 202011168321A CN 114480463 A CN114480463 A CN 114480463A
Authority
CN
China
Prior art keywords
salmonella
rbd
novel coronavirus
protein
attenuated salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011168321.4A
Other languages
English (en)
Chinese (zh)
Inventor
华子春
吴乐阳
李霖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targetpharma Laboratories Jiangsu Co ltd
Nanjing Jiruikang Biotechnology Research Institute Co ltd
Original Assignee
Targetpharma Laboratories Jiangsu Co ltd
Nanjing Jiruikang Biotechnology Research Institute Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targetpharma Laboratories Jiangsu Co ltd, Nanjing Jiruikang Biotechnology Research Institute Co ltd filed Critical Targetpharma Laboratories Jiangsu Co ltd
Publication of CN114480463A publication Critical patent/CN114480463A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202011168321.4A 2020-10-26 2020-10-27 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用 Pending CN114480463A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020111552881 2020-10-26
CN202011155288 2020-10-26

Publications (1)

Publication Number Publication Date
CN114480463A true CN114480463A (zh) 2022-05-13

Family

ID=81381681

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011168321.4A Pending CN114480463A (zh) 2020-10-26 2020-10-27 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用

Country Status (2)

Country Link
CN (1) CN114480463A (fr)
WO (1) WO2022087856A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114703214A (zh) * 2022-03-03 2022-07-05 南京吉芮康生物科技研究院有限公司 一种抗丢失时空可控表达的新型质粒及其应用
CN115716867A (zh) * 2022-11-24 2023-02-28 扬州大学 一种V型分泌系统MisL展呈表达新型冠状病毒受体结合域B细胞表位抗原和应用
CN116715737A (zh) * 2022-11-24 2023-09-08 扬州大学 新型冠状病毒受体结合域B细胞表位的靶标抗原及其在Peg菌毛展呈表达及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102335421A (zh) * 2011-08-03 2012-02-01 南京大学 一种减毒沙门氏菌诱导型分泌表达口服疫苗递呈系统及其应用
CN111529701A (zh) * 2020-05-14 2020-08-14 内蒙古自治区国际蒙医医院(内蒙古自治区蒙医药研究所) 一种口服后产生新型冠状病毒抗体的制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112687D0 (en) * 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins
CN1852921A (zh) * 2003-07-21 2006-10-25 美国政府卫生及公众服务部国家卫生协会 Sars冠状病毒刺突糖蛋白的可溶性片段
CN115960919A (zh) * 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
HUE051184T2 (hu) * 2015-11-19 2021-03-01 Univ Basel Baktériumalapú fehérjeszállítás

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102335421A (zh) * 2011-08-03 2012-02-01 南京大学 一种减毒沙门氏菌诱导型分泌表达口服疫苗递呈系统及其应用
CN111529701A (zh) * 2020-05-14 2020-08-14 内蒙古自治区国际蒙医医院(内蒙古自治区蒙医药研究所) 一种口服后产生新型冠状病毒抗体的制剂及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN G等: "Oral delivery of the Sj23LHD-GST antigen by Salmonella typhimurium type III secretion system protects against Schistosoma japonicum infection in mice", PLOS NEGLECTED TROPICAL DISEASES, vol. 5, no. 9, pages 4 *
HALIM W A等: "Evaluation of Salmonella enterica Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens", INFECTION AND IMMUNITY, vol. 80, no. 3, pages 1193 - 1202 *
杨利敏等: "新型冠状病毒疫苗研究策略分析", 生物工程学报, vol. 36, no. 4, pages 597 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114703214A (zh) * 2022-03-03 2022-07-05 南京吉芮康生物科技研究院有限公司 一种抗丢失时空可控表达的新型质粒及其应用
CN115716867A (zh) * 2022-11-24 2023-02-28 扬州大学 一种V型分泌系统MisL展呈表达新型冠状病毒受体结合域B细胞表位抗原和应用
CN115716867B (zh) * 2022-11-24 2023-08-08 扬州大学 一种V型分泌系统MisL展呈表达新型冠状病毒受体结合域B细胞表位抗原和应用
CN116715737A (zh) * 2022-11-24 2023-09-08 扬州大学 新型冠状病毒受体结合域B细胞表位的靶标抗原及其在Peg菌毛展呈表达及应用
CN116715737B (zh) * 2022-11-24 2024-02-23 扬州大学 新型冠状病毒受体结合域B细胞表位的靶标抗原及其在Peg菌毛展呈表达及应用

Also Published As

Publication number Publication date
WO2022087856A1 (fr) 2022-05-05

Similar Documents

Publication Publication Date Title
CN114480463A (zh) 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用
CN114480462A (zh) 一种减毒沙门氏菌分泌表达ntd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用
Lei et al. Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B
Crocquet-Valdes et al. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis
CN110408637B (zh) 一种草鱼出血病酵母口服疫苗及应用
Yu et al. A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice
CN114478715B (zh) 一种减毒沙门氏菌分泌表达s2结构域蛋白的新型冠状病毒疫苗递呈系统及其应用
US10251948B2 (en) Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine
Mehr et al. A DNA vaccine against Escherichia coli O157: H7
AU674311B2 (en) Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
Wang et al. Immunogenicity of viral B-cell epitopes inserted into two surface loops of the Escherichia coli K12 LamB protein and expressed in an attenuated aroA strain of Salmonella typhimurium
WO2021042947A1 (fr) Conception et utilisation de vaccin à adn minicercle
Zhang et al. Recombinant hemagglutinin protein and DNA-RNA-combined nucleic acid vaccines harbored by yeast elicit protective immunity against H9N2 avian influenza infection
CN110746496B (zh) 一种鲍曼不动杆菌的pal重组蛋白及其编码基因和它们的应用
US20240076325A1 (en) Vaccines targeting Pseudomonas aeruginosa
WO2022087855A1 (fr) Nouveau vaccin contre le coronavirus basé sur l'expression sécrétoire contrôlable de salmonella atténuée, son procédé de préparation et son application
CN107129527B (zh) 一种马链球菌兽疫亚种保护性抗原hp0623及其制备方法
Su et al. Intranasally inoculated bacterium-like particles displaying porcine epidemic diarrhea virus S1 protein induced intestinal mucosal immune response in mice
CN114703214A (zh) 一种抗丢失时空可控表达的新型质粒及其应用
EP1766008A1 (fr) Dosage de criblage phage
Jiang et al. Characterization of a mutant Listeria monocytogenes strain expressing green fluorescent protein
US20110097354A1 (en) System for the expression of peptides on the bacterial surface
CN114456240B (zh) 一种非洲猪瘟病毒基因工程亚单位口服疫苗
CN117164705B (zh) 一种靶向h5亚型禽流感病毒血凝素蛋白的纳米抗体
CN109207504B (zh) 一种有效免疫ib与nd的唾液乳酸杆菌的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination